A Phase II trial of Panitumumab with irinotecan/S-1(IRIS) as 1st-line chemotherapy for KRAS wild type metastatic colorectal cancer
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms TOHOKU POWER
- 18 Oct 2012 Planned End Date 31 Jul 2015 added as reported by University Hospital Medical Information Network - Japan.
- 01 Aug 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 24 Jul 2012 New trial record